Back to top
more

VBI Vaccines (VBIV)

(Delayed Data from NSDQ)

$0.61 USD

0.61
113,625

-0.02 (-2.45%)

Updated Apr 23, 2024 03:59 PM ET

After-Market: $0.61 0.00 (0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -111.76% and 0.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -4.62% and 71.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 42.86% and 6.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -7.05% and 40.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of -37.93% and 46.93%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Absci Corporation (ABSI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Absci Corporation (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans

by Zacks Equity Research

VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.

VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -14.29% and 85.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 8.54% and 24.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

VBI Vaccines, Inc. (VBIV) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -12.50% and 75.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Inovio Pharmaceuticals (INO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of 48.28% and 3,880%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 13.51% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

VBI Vaccine (VBIV) Inks Deal With Agenus for Brain Cancer Study

by Zacks Equity Research

VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.

VBI Vaccines, Inc. (VBIV) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -157.14% and 50.78%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of -11.70% and 9.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0% and 3.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.77% and 72.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0% and 40.88%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

NeoGenomics (NEO) delivered earnings and revenue surprises of -7.69% and 0.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for VBI Vaccines (VBIV) Stock Options

by Zacks Equity Research

Investors need to pay close attention to VBI Vaccines (VBIV) stock based on the movements in the options market lately.

VBI Vaccines, Inc. (VBIV) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 25.00% and -58.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate VBI Vaccines, Inc. (VBIV) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VBI Vaccines, Inc. (VBIV) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 12.50% and -73.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: VBI Vaccines, Inc. (VBIV) Q2 Earnings Expected to Decline

by Zacks Equity Research

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.